The Cooper Companies, Inc (COO)vsEli Lilly and Company (LLY)
COO
The Cooper Companies, Inc
$65.42
+8.58%
HEALTHCARE · Cap: $13.24B
LLY
Eli Lilly and Company
$1,102.08
+0.45%
HEALTHCARE · Cap: $1.01T
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 1608% more annual revenue ($72.25B vs $4.23B). LLY leads profitability with a 35.0% profit margin vs 5.6%. COO appears more attractively valued with a PEG of 0.68. LLY earns a higher WallStSmart Score of 76/100 (B+).
COO
Buy59
out of 100
Grade: C
LLY
Strong Buy76
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+60.3%
Fair Value
$209.19
Current Price
$65.42
$143.77 discount
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Earnings expanding 26.9% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Areas to Watch
ROE of 2.9% — below average capital efficiency
5.6% margin — thin
Premium valuation, high expectations priced in
Operating margin of -2.9%
Expensive relative to growth rate
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 31.6x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : COO
The strongest argument for COO centers on Debt/Equity, PEG Ratio, Price/Book. PEG of 0.68 suggests the stock is reasonably priced for its growth.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bear Case : COO
The primary concerns for COO are Return on Equity, Profit Margin, P/E Ratio. A P/E of 57.5x leaves little room for execution misses.
Bear Case : LLY
The primary concerns for LLY are PEG Ratio, Debt/Equity, P/E Ratio. A P/E of 40.2x leaves little room for execution misses.
Key Dynamics to Monitor
COO profiles as a value stock while LLY is a growth play — different risk/reward profiles.
COO carries more volatility with a beta of 0.87 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 59/100), backed by strong 35.0% margins and 55.5% revenue growth. COO offers better value entry with a 60.3% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
The Cooper Companies, Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
The Cooper Companies, Inc., branded as CooperCompanies, is a global medical device company headquartered in San Ramon, California.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?